Investment group Ambient Sound Investments (ASI) has agreed to invest 1.6 million euros in Estonian biotechnology drug developer Celecure to accelerate the international breakthrough of its projects.
Celecure will attend the BioEurope 2006 partnering forum in Duesseldorf, Germany to present the the latest data about itīs anti-angiogenesis compound SB101.
Swedish company Angitia AB and Estonian company Celecure AS sign a worldwide licensing agreement for a novel angiogenesis inhibitor for treatment of cancer.